Search

Displaying results 2651 - 2660 of 10000 in total
  1. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    in the patient populations being studied [A31551]. … To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected

  2. Drug

    Light mineral oil

    go.drugbank.com/drugs/DB11579
    Approved

    Mixtures: Dermaveen Dry Skin Cream
  3. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    [A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric … [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.

  4. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. … [A179422] Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

    Synonyms: -Amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl)-7-([(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene
  5. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune

    Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer Fertigspritze
  6. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  7. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]

  8. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    Desmopressin is primarily indicated for the treatment of central diabetes insipidus, primary nocturnal enuresis (bedwetting) in children, and nocturia in adults [A275458, L56104]. … First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP [A31661, A275461].

  9. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt … Davesomeran is a mRNA vaccine used in conjunction with [elasomeran] as part of the Moderna Bivalent COVID-19 vaccine.

  10. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support